-+ 0.00%
-+ 0.00%
-+ 0.00%
Dicot Pharma starts Phase 2b trial of LIB-01 for erectile dysfunction
Share
Listen to the news
Dicot Pharma starts Phase 2b trial of LIB-01 for erectile dysfunction
  • Dicot Pharma initiated a Phase 2b trial of LIB-01 for erectile dysfunction on November 18, 2026.
  • The U.S. and European study will enroll at least 200 participants to guide dose selection for Phase 3 through repeated monthly dosing.
  • An initial stage will determine the highest dose for subsequent testing; completion is expected in the first quarter of 2027.
  • Results will be generated by the trial; earlier Phase 2a findings demonstrated proof of concept.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dicot Pharma AB published the original content used to generate this news brief on November 18, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending